Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03463187 · ClinicalTrials.gov registry record · Phase 1
Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis
A Phase 1 study, sponsored by Jiangsu HengRui Medicine Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 211
- Enrollment target
NCT03463187 is a Phase 1 study that has completed, run by Jiangsu HengRui Medicine Co.. The registered enrollment target is 211 participants.
The verdict
NCT03463187, a Phase 1 study, has completed, sponsored by Jiangsu HengRui Medicine Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 211 participants
- Enrollment target
Study Summary
This is a multi-regional, randomized, double-blind, placebo-controlled, clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of SHR-1314 in adults with moderate-to-severe plaque psoriasis.
Interventions
- DRUG Placebo
- BIOLOGICAL SHR-1314
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 211 participants |
| Start Date | 2017-12-15 |
| Est. Completion | 2020-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03463187
The ClinicalTrials.gov registry entry for NCT03463187 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 211 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jiangsu HengRui Medicine Co., which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03463187 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03463187 about?
NCT03463187 is a clinical study titled "Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis". This is a multi-regional, randomized, double-blind, placebo-controlled, clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of SHR-1314 in adults with moderate-to-severe plaque psoriasis.
What is the current status of trial NCT03463187?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 211 participants. The study started on 2017-12-15. Estimated completion is 2020-08-31.
What interventions are being tested in trial NCT03463187?
The interventions under investigation include: Placebo (DRUG), SHR-1314 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03463187?
This trial is sponsored by Jiangsu HengRui Medicine Co., which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.